China Aoxing Pharmaceutical Company Receives GMP Certification for Tablet Dosage Form of Pharmaceutical Products

NEW YORK, NY, Apr 20 (MARKET WIRE) --
China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) ("China Aoxing"),
a China-based pharmaceutical company specializing in research,
development, manufacturing and distribution of narcotic and
pain-management products, today announced that it has received the Good
Manufacturing Practice (GMP) certification for its recently opened tablet
formulation and packaging production facility. The certificate of
compliance has a five-year term and was issued by the State Food and Drug
Administration (SFDA) following a site inspection.

"Good Manufacturing Practice" is a body of internationally accepted
regulations set forth by drug agencies at many countries. GMP compliance
ensures that pharmaceuticals, active ingredients and medical devices are
produced and quality-controlled according to state-of-the-art standards.

"GMP compliance is the gold standard in quality assurance in the life
science industry. It is a major achievement for us to receive this
particular GMP certification in early 2009," said Juan Yue Han, Chairman
and the CEO of China Aoxing. "This provides the foundation for the further
development of China Aoxing. We are well positioned to manufacture
pharmaceutical products in tablet dosage form in our modern production
facility, as we are preparing for the launch of several important narcotic
drugs in tablet dosage form in the foreseeable future, including Tilidine,
Oxycodone, Buprenorphine and others, which provide well established
medical benefit in treating cancer pain, moderate to severe pain, or
related chronic health problems."

About China Aoxing Pharmaceutical Company, Inc.

China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) is a
pharmaceutical company located in China specializing in research,
development, manufacturing and distribution of a variety of narcotics and
pain-management products. Headquartered in Shijiazhuang City, the
pharmaceutical capital of China, outside of Beijing, China Aoxing has
China's largest and the most advanced manufacturing facility for highly
regulated narcotic medicines, addressing a very under-served and
fast-growing market in China. Its facility is one of the few GMP
facilities licensed for narcotics medicines. The Company is working
closely with the Chinese government and SFDA to assure the strictly
regulated availability to medical professionals of its narcotic drugs and
pain medicines throughout China.

Statements made in this press release are forward-looking and are made
pursuant to the safe harbor provisions of the Securities Litigation Reform
Act of 1995. Such statements involve risks and uncertainties that may
cause actual results to differ materially from those set forth in these
statements. The economic, competitive, governmental, technological and
other risk factors identified in the Company's filings with the Securities
and Exchange Commission, including the Form 10-KSB for the year ended June
30, 2008, may cause actual results or events to differ materially from
those described in the forward looking statements in this press release.
The Company undertakes no obligation to publicly update or revise any
forward-looking statements, whether because of new information, future
events, or otherwise.

Contact:

Wei Zhang
Investor Relations
China Aoxing Pharmaceutical Company, Inc.
Email: chinaaoxing@gmail.com
Telephone: 646 - 512 - 5662

Copyright 2009, Market Wire, All rights reserved.

-0-